A
Alberto Lázaro
Researcher at Hospital General Universitario Gregorio Marañón
Publications - 47
Citations - 1306
Alberto Lázaro is an academic researcher from Hospital General Universitario Gregorio Marañón. The author has contributed to research in topics: Nephrotoxicity & Cilastatin. The author has an hindex of 20, co-authored 42 publications receiving 1129 citations. Previous affiliations of Alberto Lázaro include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Elemental Bioimaging in Kidney by LA–ICP–MS As a Tool to Study Nephrotoxicity and Renal Protective Strategies in Cisplatin Therapies
Estefanía Moreno-Gordaliza,Charlotte Giesen,Charlotte Giesen,Alberto Lázaro,Diego Esteban-Fernández,Blanca Humanes,Benito Cañas,Ulrich Panne,Ulrich Panne,Alberto Tejedor,Norbert Jakubowski,M. Milagros Gómez-Gómez +11 more
TL;DR: Pt turned out to accumulate in the kidney cortex and corticomedullary junction, corresponding to areas where the proximal tubule S3 segments (the most sensitive cells to cisplatin nephrotoxicity) are located, demonstrating the connection between platinum accumulation and renal damage proved by histological examination of HE-stained sections.
Journal ArticleDOI
Proteomic analysis of human vessels: application to atherosclerotic plaques.
Mari Carmen Duran,Sebastian Mas,José Luis Martín-Ventura,Olivier Meilhac,Jean-Baptiste Michel,Julio Gallego-Delgado,Alberto Lázaro,José Tuñón,Jesús Egido,Fernando Vivanco +9 more
TL;DR: The more complicated the lesion, the higher the number of secreted proteins, suggesting the production of specific proteins relating to the complexity of the atherosclerotic lesion.
Journal ArticleDOI
Fcγ Receptor Deficiency Confers Protection Against Atherosclerosis in Apolipoprotein E Knockout Mice
Purificación Hernández-Vargas,Guadalupe Ortiz-Muñoz,Oscar Lopez-Franco,Yusuke Suzuki,Julio Gallego-Delgado,Guillermo Sanjuán,Alberto Lázaro,Virginia Lopez-Parra,Luis Angel Ortega,Jesús Egido,Carmen Gomez-Guerrero +10 more
TL;DR: It is concluded that Fc&ggr;R deficiency limits development and progression of atherosclerosis and support the use of immunotherapy in the treatment of this disease.
Journal ArticleDOI
Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression
Esmeralda Castillo-Rodriguez,Raul Fernandez-Prado,Raquel Esteras,Maria Vanessa Perez-Gomez,Carolina Gracia-Iguacel,Beatriz Fernandez-Fernandez,Mehmet Kanbay,Alberto Tejedor,Alberto Lázaro,Marta Ruiz-Ortega,Emilio González-Parra,Ana Belen Sanz,Alberto Ortiz,Maria Dolores Sanchez-Niño +13 more
TL;DR: Specific focus will be placed on the generation specific uremic toxins with nephrotoxic potential, the decreased availability of bacteria-derived metabolites withNephroprotective potential, such as vitamin K and butyrate and the cellular and molecular mechanisms linking these toxins and protective factors to kidney diseases.
Journal ArticleDOI
Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats
Blanca Humanes,Alberto Lázaro,Sonia Camaño,Estefanía Moreno-Gordaliza,Jose A. Lazaro,Montserrat Blanco-Codesido,Jose Manuel Lara,Alberto Ortiz,María Milagros Gómez-Gómez,Pablo Martín-Vasallo,Alberto Tejedor +10 more
TL;DR: Cilastatin, a small molecule inhibitor of renal dehydropeptidase I, prevents proximal tubular cells from undergoing cisplatin-induced apoptosis in vitro as mentioned in this paper.